Discover
ozanimod (RPC1063) / CelgeneOzanimod clinical trial estimate: Data from P3 TRUE NORTH trial (NCT02435992) for moderate-to-severe ulcerative colitis in mid-2020 (Guggenheim) - Oct 8, 2019 - A subscription to Thomson ONE is required to gain full access to report 68001013; Page no: 2; REPORT TITLE: "Highlights from our autoImmune/immunology KOL series Part 3: Emerging treatment landscape in Crohn's Disease and ulcerative colitis”; AUTHOR: Fernandez, Seamus, et al; DATE: 09/24/2019filgotinib (GLPG0634) / GileadFilgotinib clinical trial estimate: Topline data from P2b/3 SELECTION1 trial (NCT02914522) for ulcerative colitis in H1 2020 (Cantor Fitzgerald) - Oct 10, 2019 - A subscription to Thomson ONE is required to gain full access to report 68016498; Page no: 1; REPORT TITLE: "Cantor conference class of 2019: Top questions, catalysts, and who is most likely to....”; AUTHOR: Research Department; DATE: 09/26/2019Myoconda (clarithromycin/clofazimine/rifabutin) / RedHillRedHill Biopharma Announces Full Results from Positive MAP US Phase 3 Study and Supportive Top-Line Results from MAP US2 Open-Label Extension Study with RHB-104 in Crohn’s Disease (GlobeNewswire, RedHill Biopharma Ltd.) - Oct 11, 2019 - P3, N=330; MAPUS (NCT01951326); P3, N=331; MAPUS2 (NCT03009396); Sponsor: NCT01951326; "RedHill Biopharma Ltd...announced full Week 52 results for all subjects in the previously announced positive Phase 3 randomized, controlled study of RHB-104 in Crohn’s disease (the 'MAP US study') and supportive top-line results from the open-label extension Phase 3 study (the 'MAP US2 study'). The full Week 52 results of blinded treatment in the MAP US Phase 3 study....continued to meet its primary endpoint..."Xeljanz (tofacitinib) / PfizerXeljanz US sales projection: $2.7B in 2024 (Infinata) - Oct 12, 2019 - A subscription to Thomson ONE is required to gain full access to report 68065169; Page no: 14; REPORT TITLE: "Pfizer, Inc. - Company report”; AUTHOR: Infinata, et al; DATE: 10/07/2019Stelara (ustekinumab) / J&JStelara patent expiry: September 2023 in US (Edison Investment Research) - Oct 11, 2019 - A subscription to Thomson ONE is required to gain full access to report 68038761; Page no: 4; REPORT TITLE: "Formycon - H119 results – FYB201 FDA filing imminent”; AUTHOR: Savin, John, et al; DATE: 10/02/2019Humira (adalimumab) / Eisai, AbbVie; Remicade (infliximab) / Mitsubishi Tanabe, J&JHLA-DQA1*05 carriage associated with development of anti-drug antibodies to infliximab and adalimumab in patients with Crohn’s disease (Gastroenterology) - Oct 7, 2019 - P=NA, N=1,240; "We performed a genome-wide association study to identify variants associated with time to development of anti-drug antibodies in...patients with Crohn’s disease starting infliximab or adalimumab therapy...In an observational study, we found a genome-wide significant association between HLA-DQA1*05 and the development of antibodies against anti-TNF agents."Otezla (apremilast) / AmgenOtezla sales projection: $4B in 2027 (Oppenheimer) - Oct 8, 2019 - A subscription to Thomson ONE is required to gain full access to report 68004961; Page no: 1; REPORT TITLE: "Amgen Inc- Key takeaways from meeting with management”; AUTHOR: Research Department; DATE: 09/24/2019
